XML 44 R38.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information (Tables)
9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Summary of significant segment expenses and segment net loss

The following table summarizes our significant segment expenses and segment net loss for the three and nine months ended September 30, 2025 and 2024 (in thousands):

 

For the three months ended September 30,

 

 

For the nine months ended September 30,

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Canvuparatide direct program expense

 

$

10,130

 

 

$

5,957

 

 

$

27,390

 

 

$

14,920

 

MBX 4291 direct program expense

 

 

2,669

 

 

 

5,514

 

 

 

10,991

 

 

 

7,659

 

Imapextide direct program expense

 

 

618

 

 

 

2,066

 

 

 

3,411

 

 

 

9,810

 

Preclinical and other research and development direct expense

 

 

1,466

 

 

 

194

 

 

 

4,316

 

 

 

769

 

Research and development overhead expense

 

 

4,387

 

 

 

3,016

 

 

 

13,292

 

 

 

9,034

 

Other segment items (1)

 

 

2,348

 

 

 

1,395

 

 

 

5,509

 

 

 

4,144

 

Net loss

 

$

21,618

 

 

$

18,142

 

 

$

64,909

 

 

$

46,336

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) Other segment items are primarily comprised of general and administrative expenses and interest and other income.